Charles River Laboratories International, Inc. (NYSE:CRL) Director Richard F. Wallman Acquires 1,000 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director Richard F. Wallman acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $198,790. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $203.89 on Wednesday. The firm has a 50 day moving average of $206.74 and a 200-day moving average of $205.60. The stock has a market capitalization of $10.45 billion, a PE ratio of 21.62, a PEG ratio of 1.80 and a beta of 1.33. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. Charles River Laboratories International, Inc. has a 12 month low of $181.22 and a 12 month high of $262.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $2.69 EPS for the quarter, beating the consensus estimate of $2.63 by $0.06. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.77 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on CRL shares. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Charles River Laboratories International from $260.00 to $250.00 in a research note on Friday, May 12th. Bank of America lifted their price target on shares of Charles River Laboratories International from $235.00 to $245.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. Wells Fargo & Company lowered their price target on shares of Charles River Laboratories International from $290.00 to $280.00 in a research note on Friday, May 12th. Finally, Citigroup downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $260.00 to $225.00 in a research report on Monday, July 10th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $247.80.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. Moneta Group Investment Advisors LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at approximately $298,877,000. Price T Rowe Associates Inc. MD increased its position in Charles River Laboratories International by 35.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after purchasing an additional 653,790 shares in the last quarter. Norges Bank acquired a new position in Charles River Laboratories International during the 4th quarter worth approximately $97,675,000. BlackRock Inc. increased its position in Charles River Laboratories International by 8.6% during the 2nd quarter. BlackRock Inc. now owns 5,198,037 shares of the medical research company’s stock worth $1,092,887,000 after purchasing an additional 411,153 shares in the last quarter. Finally, Southpoint Capital Advisors LP acquired a new position in Charles River Laboratories International during the 1st quarter worth approximately $80,728,000. 98.55% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).